Mechanisms of tissue remodeling in inflammatory bowel disease

Digestive Diseases

Volumn 31, Issue 2, 2013, Pages 186-193

  Rieder, Florian ^a   Fiocchi, Claudio ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Disease course; Fibrosis; Fistula; Inflammatory bowel disease

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CALVASCULIN; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; FIBRONECTIN; INTERLEUKIN 1; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 4; PATTERN RECOGNITION RECEPTOR; PLATELET DERIVED GROWTH FACTOR; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA1; VIMENTIN;

ARTICLE; CELL MIGRATION; CROHN DISEASE; ENTERITIS; ENVIRONMENTAL FACTOR; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; FIBROGENESIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTESTINAL FIBROSIS; INTESTINE FLORA; MESENCHYME CELL; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; CHRONIC INFLAMMATION; DISEASE COURSE; INFLAMMATORY BOWEL DISEASE; INTESTINE FISTULA; INTESTINE OBSTRUCTION; INTESTINE PERFORATION; TISSUE REMODELING; TISSUE REPAIR;

ANIMALS; DISEASE MODELS, ANIMAL; ENVIRONMENT; FIBROSIS; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINES; MESODERM;

EID: 84884248502     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000353364     Document Type: Article

References (62)

1. Medzhitov R: Origin and physiological roles of inflammation. Nature 2008; 454: 428-435.
2. Rieder F, Fiocchi C: Intestinal fibrosis in IBD-a dynamic, multifactorial process. Nat Rev Gastroenterol Hepatol 2009; 6: 228-235.
3. Cosnes J, Nion-Larmurier I, Beaugerie L, Afchain P, Tiret E, Gendre JP: Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut 2005; 54: 237-241.
4. Farmer RG, Whelan G, Fazio VW: Long-term follow-up of patients with Crohn's disease. Relationship between the clinical pattern and prognosis. Gastroenterology 1985; 88: 1818-1825.
5. Peyrin-Biroulet L, Oussalah A, Williet N, Pillot C, Bresler L, Bigard MA: Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn's disease. Gut 2011; 60: 930-936.
6. Friedman SL, Sheppard D, Duffield JS, Violette S: Therapy for fibrotic diseases: nearing the starting line. Sci Transl Med 2013; 5: 167sr161.
7. Rieder F, Brenmoehl J, Leeb S, Scholmerich J, Rogler G: Wound healing and fibrosis in intestinal disease. Gut 2007; 56: 130-139.
8. Kugathasan S, Saubermann LJ, Smith L, Kou D, Itoh J, Binion DG, Levine AD, Blumberg RS, Fiocchi C: Mucosal T-cell immunoregulation varies in early and late inflammatory bowel disease. Gut 2007; 56: 1696-1705.
9. Wynn TA, Ramalingam TR: Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med 2012; 18: 1028-1040.
10. Spencer DM, Veldman GM, Banerjee S, Willis J, Levine AD: Distinct inflammatory mechanisms mediate early versus late colitis in mice. Gastroenterology 2002; 122: 94-105.
11. Bowen T, Jenkins RH, Fraser DJ: Micrornas, transforming growth factor beta-1, and tissue fibrosis. J Pathol 2013; 229: 274-285.
12. Sadler T, Scarpa M, Rieder F, West G, Stylianou E: Cytokine-induced chromatin modifications of the type I collagen alpha 2 gene during intestinal endothelial-to-mesenchymal transition. Inflamm Bowel Dis 2013; 19: 1354-1364.
13. Lawrance IC, Maxwell L, Doe W: Altered response of intestinal mucosal fibroblasts to profibrogenic cytokines in inflammatory bowel disease. Inflamm Bowel Dis 2001; 7: 226-236.
14. Berton A, Levi-Schaffer F, Emonard H, Garbuzenko E, Gillery P, Maquart FX: Activation of fibroblasts in collagen lattices by mast cell extract: a model of fibrosis. Clin Exp Allergy 2000; 30: 485-492.
15. Xu X, Rivkind A, Pikarsky A, Pappo O, Bischoff SC, Levi-Schaffer F: Mast cells and eosinophils have a potential profibrogenic role in Crohn disease. Scand J Gastroenterol 2004; 39: 440-447.
16. Meier JK, Scharl M, Miller SN, Brenmoehl J, Hausmann M, Kellermeier S, Scholmerich J, Rogler G: Specific differences in migratory function of myofibroblasts isolated from Crohn's disease fistulae and strictures. Inflamm Bowel Dis 2011; 17: 202-212.
17. Leeb SN, Vogl D, Grossmann J, Falk W, Scholmerich J, Rogler G, Gelbmann CM: Autocrine fibronectin-induced migration of human colonic fibroblasts. Am J Gastroenterol 2004; 99: 335-340.
18. Leeb SN, Vogl D, Gunckel M, Kiessling S, Falk W, Goke M, Scholmerich J, Gelbmann CM, Rogler G: Reduced migration of fibroblasts in inflammatory bowel disease: role of inflammatory mediators and focal adhesion kinase. Gastroenterology 2003; 125: 1341-1354.
19. Rieder F, Georgieva M, Schirbel A, Artinger M, Zugner A, Blank M, Brenmoehl J, Scholmerich J, Rogler G: Prostaglandin E2 inhibits migration of colonic lamina propria fibroblasts. Inflamm Bowel Dis 2010; 16: 1505-1513.
20. Kalluri R, Neilson EG: Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 2003; 112: 1776-1784.
21. Zeisberg M, Yang C, Martino M, Duncan MB, Rieder F, Tanjore H, Kalluri R: Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. J Biol Chem 2007; 282: 23337-23347.
22. Frid MG, Kale VA, Stenmark KR: Mature vascular endothelium can give rise to smooth muscle cells via endothelial-mesenchymal transdifferentiation: in vitro analysis. Circ Res 2002; 90: 1189-1196.
23. Zeisberg EM, Tarnavski O, Zeisberg M, Dorfman AL, McMullen JR, Gustafsson E, Chandraker A, Yuan X, Pu WT, Roberts AB, Neilson EG, Sayegh MH, Izumo S, Kalluri R: Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med 2007; 13: 952-961.
24. Rieder F, Kessler SP, West GA, Bhilocha S, de la Motte C, Sadler TM, Gopalan B, Stylianou E, Fiocchi C: Inflammation-induced endothelial-to- mesenchymal transition: a novel mechanism of intestinal fibrosis. Am J Pathol 2011; 179: 2660-2673.
25. Flier SN, Tanjore H, Kokkotou EG, Sugimoto H, Zeisberg M, Kalluri R: Identification of epithelial to mesenchymal transition as a novel source of fibroblasts in intestinal fibrosis. J Biol Chem 2010; 285: 20202-20212.
26. Bataille F, Rohrmeier C, Bates R, Weber A, Rieder F, Brenmoehl J, Strauch U, Farkas S, Furst A, Hofstadter F, Scholmerich J, Herfarth H, Rogler G: Evidence for a role of epithelial mesenchymal transition during pathogenesis of fistulae in Crohn's disease. Inflamm Bowel Dis 2008; 14: 1514-1527.
27. Scharl M, Frei S, Pesch T, Kellermeier S, Arikkat J, Frei P, Fried M, Weber A, Jehle E, Ruhl A, Rogler G: Interleukin-13 and transforming growth factor beta synergise in the pathogenesis of human intestinal fistulae. Gut 2013; 62: 63-72.
28. Xavier RJ, Podolsky DK: Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007; 448: 427-434.
29. Ng SC, Bernstein CN, Vatn MH, Lakatos PL, Loftus EV Jr, Tysk C, O'Morain C, Moum B, Colombel JF: Geographical variability and environmental risk factors in inflammatory bowel disease. Gut 2013; 62: 630-649.
30. Rappaport SM: Discovering environmental causes of disease. J Epidemiol Community Health 2012; 66: 99-102.
31. Takeuchi O, Akira S: Pattern recognition receptors and inflammation. Cell 2010; 140: 805-820.
32. Uehara A, Takada H: Functional TLRs and NODs in human gingival fibroblasts. J Dent Res 2007; 86: 249-254.
33. Seki E, Brenner DA: Toll-like receptors and adaptor molecules in liver disease: update. Hepatology 2008; 48: 322-335.
34. Seki E, De Minicis S, Osterreicher CH, Kluwe J, Osawa Y, Brenner DA, Schwabe RF: TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med 2007; 13: 1324-1332.
35. Miyazaki H, Kobayashi R, Ishikawa H, Awano N, Yamagoe S, Miyazaki Y, Matsumoto T: Activation of COL1A2 promoter in human fibroblasts by Escherichia coli. FEMS Immunol Med Microbiol 2012; 65: 481-487.
36. Burke JP, Cunningham MF, Watson RW, Docherty NG, Coffey JC, O'Connell PR: Bacterial lipopolysaccharide promotes profibrotic activation of intestinal fibroblasts. Br J Surg 2010; 97: 1126-1134.
37. Lin RS, Lee FY, Lee SD, Tsai YT, Lin HC, Lu RH, Hsu WC, Huang CC, Wang SS, Lo KJ: Endotoxemia in patients with chronic liver diseases: relationship to severity of liver diseases, presence of esophageal varices, and hyperdynamic circulation. J Hepatol 1995; 22: 165-172.
38. Chan CC, Hwang SJ, Lee FY, Wang SS, Chang FY, Li CP, Chu CJ, Lu RH, Lee SD: Prognostic value of plasma endotoxin levels in patients with cirrhosis. Scand J Gastroenterol 1997; 32: 942-946.
39. Isayama F, Hines IN, Kremer M, Milton RJ, Byrd CL, Perry AW, McKim SE, Parsons C, Rippe RA, Wheeler MD: LPS signaling enhances hepatic fibrogenesis caused by experimental cholestasis in mice. Am J Physiol Gastrointest Liver Physiol 2006; 290:G1318-G1328.
40. Otte JM, Rosenberg IM, Podolsky DK: Intestinal myofibroblasts in innate immune responses of the intestine. Gastroenterology 2003; 124: 1866-1878.
41. Rieder F, Bhilocha S, Schirbel A, Ouyang Z, West G, Atreja A, Rho H, De La Motte C, Fiocchi C: Activation of toll-like receptor (TLR) 5 induces a pro-fibrogenic phenotype on human intestinal myofibroblasts (HIF)-a novel pathway mediated by caspase 1 (abstract). Gastroenterology 2011; 142:S116.
42. Hasan UA, Trinchieri G, Vlach J: Toll-like receptor signaling stimulates cell cycle entry and progression in fibroblasts. J Biol Chem 2005; 280: 20620-20627.
43. Eyking A, Ey B, Runzi M, Roig AI, Reis H, Schmid KW, Gerken G, Podolsky DK, Cario E: Toll-like receptor 4 variant D299G induces features of neoplastic progression in Caco-2 intestinal cells and is associated with advanced human colon cancer. Gastroenterology 2012; 141: 2154-2165.
44. Franke A, McGovern DP, Barrett JC, Wang K, et al: Genome-wide meta-analysis increases to 71. the number of confirmed Crohn's disease susceptibility loci. Nat Genet 2010; 42: 1118-1125.
45. Adler J, Rangwalla SC, Dwamena BA, Higgins PD: The prognostic power of the NOD2 genotype for complicated Crohn's disease: a meta-analysis. Am J Gastroenterol 2011; 106: 699-712.
46. Weersma RK, Stokkers PC, Cleynen I, Wolfkamp SC, Henckaerts L, Schreiber S, Dijkstra G, Franke A, Nolte IM, Rutgeerts P, Wijmenga C, Vermeire S: Confirmation of multiple Crohn's disease susceptibility loci in a large Dutch-Belgian cohort. Am J Gastroenterol 2009; 104: 630-638.
47. Morgan XC, Tickle TL, Sokol H, Gevers D, Devaney KL, Ward DV, Reyes JA, Shah SA, LeLeiko N, Snapper SB, Bousvaros A, Korzenik J, Sands BE, Xavier RJ, Huttenhower C: Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol 2012; 13:R79.
48. Frank DN, Robertson CE, Hamm CM, Kpadeh Z, Zhang T, Chen H, Zhu W, Sartor RB, Boedeker EC, Harpaz N, Pace NR, Li E: Disease phenotype and genotype are associated with shifts in intestinal-associated microbiota in inflammatory bowel diseases. Inflamm Bowel Dis 2011; 17: 179-184.
49. Sokol H, Lay C, Seksik P, Tannock GW: Analysis of bacterial bowel communities of IBD patients: what has it revealed? Inflamm Bowel Dis 2008; 14: 858-867.
50. Rieder F, Lawrance IC, Leite A, Sans M: Predictors of fibrostenotic Crohn's disease. Inflamm Bowel Dis 2011; 17: 2000-2007.
51. Rivera-Nieves J, Bamias G, Vidrich A, Marini M, Pizarro TT, McDuffie MJ, Moskaluk CA, Cohn SM, Cominelli F: Emergence of perianal fistulizing disease in the SAMP1/YitFc mouse, a spontaneous model of chronic ileitis. Gastroenterology 2003; 124: 972-982.
52. Rieder F, Kessler S, Sans M, Fiocchi C: Animal models of intestinal fibrosis: new tools for the understanding of pathogenesis and therapy of human disease. Am J Physiol Gastrointest Liver Physiol 2012; 303:G786-G801.
53. Pucilowska JB, Williams KL, Lund PK: Fibrogenesis. IV. Fibrosis and inflammatory bowel disease: cellular mediators and animal models. Am J Physiol Gastrointest Liver Physiol 2000; 279:G653-G659.
54. Mourelle M, Salas A, Guarner F, Crespo E, Garcia-Lafuente A, Malagelada JR: Stimulation of transforming growth factor beta1 by enteric bacteria in the pathogenesis of rat intestinal fibrosis. Gastroenterology 1998; 114: 519-526.
55. Duffield JS, Lupher M, Thannickal VJ, Wynn TA: Host responses in tissue repair and fibrosis. Annu Rev Pathol 2013; 8: 241-276.
56. Deretic V, Jiang S, Dupont N: Autophagy intersections with conventional and unconventional secretion in tissue development, remodeling and inflammation. Trends Cell Biol 2012; 22: 397-406.
57. Del Principe D, Lista P, Malorni W, Giammarioli AM: Fibroblast autophagy in fibrotic disorders. J Pathol 2013; 229: 208-220.
58. Johnson LA, Luke A, Sauder K, Moons DS, Horowitz JC, Higgins PD: Intestinal fibrosis is reduced by early elimination of inflammation in a mouse model of IBD: Impact of a 'top-down' approach to intestinal fibrosis in mice. Inflamm Bowel Dis 2012; 18: 460-471.
59. Feagan BG, Panaccione R, Sandborn WJ, D'Haens GR, Schreiber S, Rutgeerts PJ, Loftus EV Jr, Lomax KG, Yu AP, Wu EQ, Chao J, Mulani P: Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the charm study. Gastroenterology 2008; 135: 1493-1499.
60. Wells RG: The role of matrix stiffness in regulating cell behavior. Hepatology 2008; 47: 1394-1400.
61. Al-Hawary M, Zimmermann EM: A new look at Crohn's disease: novel imaging techniques. Curr Opin Gastroenterol 2012; 28: 334-340.
62. Rieder F, Zimmermann EM, Remzi FH, Sandborn WJ: Crohn's disease complicated by strictures: a systematic review. Gut 2013; 62: 1072-1084.